Table of Contents
- Pan-HDAC Inhibitors in Oncology Indications
- Sub-Class Selective HDAC Inhibitors in Oncology
- Multi--Specific HDAC Inhibitors
- HDAC Inhibitors in Non-Oncology Indications
- Corporate HDAC Inhibitor R&D Pipelines
- About La Merie
Corporate HDAC Inhibitor Product and R&D Pipelines
- 4SC
- Access Pharmaceuticals
- Arno Therapeutics
- Celleron Therapeutics
- Chroma Therapeutics
- Crystal Genomics
- Curis
- EnVivo Pharmaceuticals
- Ethical Oncology Science (EOS)
- Exon Hit Therapeutics
- Genextra (DAC)
- GlaxoSmithKline (GSK)
- Gloucester Pharmaceuticals
- HUYA Bioscience International
- Italfarmaco
- Johnson & Johnson (J&J)
- Karus Therapeutics
- Menarini
- Merck & Co
- MethylGene
- Novartis
- Pharmacyclics
- Repligen
- S*Bio
- Servier
- Shenzhen Chipscreen Biosciences
- Sigma Tau
- Syndax Pharmaceuticals
- Taiho Pharmaceutical Co.
- Topotarget
|
Related Report
|
View Cart
